Publications
Home

  1. Salvatore MF, Fisher B, Surgener SP, Gerhardt GA, and Roualut T. Neurochemical investigations of dopamine neural systems in iron-regulatory protein 2 (IRP-2) knockout mice. Mol Brain Res 139:341-347, 2005. PMID: 16051392
  2. Gash DM, Zhang Z, Ai Y, Grondin R, Coffey R, and Gerhardt GA. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann Neurol 58(2):224-33, 2005. PMID: 16049934
  3. Penn R, Dalvi A, Slevin J, Young B, Gash D, Gerhardt GA, Hutchinson M. GDNF in treatment of Parkinson's disease: response to editorial. The Lancet Neurology, 5(3): 202-203, 2006. PMID: 16488374
  4. Slevin JT, Gerhardt GA, Smith CD, Gash DM, and Young AB. Reply: GDNF poses troubling questions for doctors, drug maker. Ann Neurol. 59(6):989-990, 2006. PMID:16711657
  5. Slevin JT, Gash DM, Smith CD, Gerhardt GA, Kryscio R, Chebrolu H, Walton A, Wagner R, and Young AB. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal. J Neurosurg. 106(4):614-20, 2007. PMID: 17432712
  6. Salvatore MF, Ai Y, Fischer B, Zhang AM, Grondin RC, Zhang Z, Gerhardt GA and Gash DM. Point source concentration of GDNF may explain failure of Phase II clinical trial. Exp Neurol 202(2):497-505, 2006. (Epub 2006 Sep. 7) PMID: 16962582
  7. Zhang Z, Andersen AH, Ai Y, Loveland A, Hardy PA, Gerhardt GA and Gash DM. Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques. Neuroimage 33(2):636-43, 2006. (Epub 2006 Sep. 1) PMID: 16949305
  8. Cass, WA, Grondin R, Andersen AH, Zhang Z, Hardy PA, Hussey-Andersen LK, Rayens WS, Gerhardt GA and Gash DM. Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys. Neurobiology of Aging 28(2):258-71, 2007. PMID: 16442671
  9. Stanford JA, Salvatore MF, Joyce BM, Zhang H, Gash DM and Gerhardt GA. Bilateral effects of unilateral intrastriatal GDNF on locomotor-excited and nonlocomotor-related striatal neurons in aged F344 rats. Neurobio Aging 28:156-165, 2007. (Epub 2005 Nov 28) PMID: 16314001
  10. Smith CD, Walton A, Slevin JT, Gerhardt GA, Umberger G, Smoot K, Schulze E and Gash DM. Validation studies of the human motor activities panel for Hand/Arm Performance. J Neurosci Meth 165:287-296, 2007. (Epub 2007 Jun 22) PMC2074932, NIHMS29682
  11. Quintero JE, Day BK, Zhang Z, Grondin R, Stephens ML, Huettl P, Pomerleau F, Gash DM, Gerhardt GA. Rapid amperometric measures of age-related changes in glutamate regulation in cortex of rhesus monkeys. Exp Neurol Dec; 208(2):238-246, 2007. (Epub 2007 Aug 22) PMID: 17927982
  12. Gash DM, Rutland K, Hudson JL, Sullivan PG, Bing G, Cass WA, Pandya JD, Liu M, Choi D-Y, Hunter RL, Gerhardt GA, Smith CD, Slevin JT and Prince TS. Trichloroethylene: Parkinsonism and Complex I Mitochondrial Neurotoxicity. Ann Neurol Feb; 63(2):184-92, 2008. PMID: 18157908
  13. Xin T. Ai Y, Gerhardt GA, Gash and Zhang Z. Globus pallidus plays a critical role in neurotrophic factor induced functional improvements in hemiparkinsonian monkeys. Biochem Biophys Res Comm Biochem Biophys Res Commun. Jun 6;370(3):434-9, 2008. (Epub 2008 Mar 31) PMCID: PMC2682325
  14. Grondin R, Zhang Z, Ai Y, Ding F, Walton AA, Surgener SP, Gerhardt GA and Gash DM. Intraputamenal infusion of exogenous neuturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys. Cell Transplantation 17(4):373-81, 2008. PMCID: PMC2680490
  15. Ding F, Luan L, Ai Y, Walton A, Gerhardt GA, Gash DM, Grondin R and Zhang Z. Development of a stable, early stage unilateral model of Parkinson's disease in middle-aged rhesus monkeys. Exp Neuron 212(2):431-9, 2008. [Epub ahead of print] PMCID: PMC2527750
  16. Zaman V, Boger HA, Granholm A-C, Rohrer B, Moore A, Buhusi M, Gerhardt GA, Hoffer BJ and Middaugh LD. The nigrostriatal dopamine system of aging GFR-1 heterozygous mice: neurochemistry, morphology and behavior. Eur J Neurosci 28(8):1557-68, 2008. PMC2704551, NIHMS105188
  17. Lundblad M, af Bjerkén S, Cenci MA, Pomerleau F, Gerhardt GA and Strömberg I. Chronic intermittent L-DOPA treatment induces changes in dopamine release. J Neurochem 108(4):998-1008, 2009. PMID: 19196428
  18. Stephens, ML, Pomerleau F, Huettl P, Gerhardt GA and Zhang Z. Real-time glutamate measurements in the putamen of awake rhesus monkeys using an enzyme-based human microelectrode array prototype. J Neuro Meth, 185(2):264:72, 2010. Epub 2009 Oct 20. PMCID: PMC2815042, NIHMS153577
  19. Bradley LH, Fuqua J, Richard A, Turchan-Cholewo J, Ai, Y, Kelps KA, Glass JD, He X, Zhang Z, Grondin R, Littrell OM, Huettl P, Pomerleau F, Gash DM and Gerhardt GA. Dopamine neuron stimulating actions of a GDNF propeptide. PLoS One Biology 5(3):e9752, 2010. PMCID: PMC2841203.
  20. Zhang, Z, Fan X, Grondin R, Edwards R, Forman E, Moorehead J and Gerhardt GA. Electroacupuncture and Electromyographic Recordings in Normal and Parkinsonian Rhesus Monkeys. J. Neurosci. Meth., in press, 2010.
  21. Unilateral Intraputamenal GDNF improves bilateral motor functions in patients with Parkinson’s disease.  Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, and Young AB.  J Neurosurg 102:216-222, 2005.
  22. In vivo electrochemical studies of d-amphetamine and d,l-amphetamine-induced dopamine release in the rat striatum and nucleus accumbens core. Glaser PEA, Currier TD, Joyce BM, Castellanos FX and Gerhardt GA.  Psychopharmacology (in press), 2005.
  23. Neurodegenerative alterations in the nigrostriatal system of trkB hypomorphic mice.  Zaman V, Nelson ME, Gerhardt GA and Rohrer B.  Exp. Neurol. 190(2):337-46, 2004.
  24. Aged related changes in the dynamics of potassium-evoked l-glutamate release in the striatum of Fischer 344 rats.  Nickell J, Pomerleau F, Allen J and Gerhardt GA.  J Neural Transm. 112(1):87-96, 2004.
  25. Caloric restriction increases GDNF levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson’s disease.  Maswood N, Young J, Tilmont E, Zhang Z, Gash DM, Gerhardt GA, Grondin R, Yi A, Roth GS, Lane MA, Carson R, Cohen RM, Mouton PM, Mattson MP, Ingram DK.  PNAS, 101(52):18171-18176, 2004.
  26. Beneficial effects of intraventricularly administered BMP-7 following a striatal 6-hydroxydopamine lesion. Zuch CL, David D, Ujhelyi L, Hudson JL, Gerhardt GA, Kaplan PL and Bickford PC.  Brain Res 1010:10-16, 2004.
  27. Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra.  Salvatore MF, Zhang J-L, Large DM, Wilson PE, Gash CR, Thomas TD, Haycock, JW, Bing G, Stanford JA, Gash DM and Gerhardt GA.  J Neurochem 90(1):245-254, 2004.
  28. Aged F344 rats exhibit altered electrophysiological activity in locomotor-unrelated but not locomotor-related striatal neurons.  Stanford JA and Gerhardt GA.  Neurobio Aging  25:509-515, 2004.
  29. Prenatal cocaine exposure alters potassium-evoked dopamine research dynamics in rat striatum.  Salvatore, MF, Hudspeth O, Arnold LE, Wilson PE, Stanford JA, Mactutus CF, Booze RM and Gerhardt GA.  Neuroscience 123:481-490, 2003.
  30.  Differential effects of post-implantation time on potassium- versus d-amphetamine-evoked DA overflow in the striatum of F344 rats.  Purdom MS, Stanford JA and Gerhardt GA. Neurosci Ltrs, 348(2):97-100, 2003.
  31. Microdialysis studies of d-amphetamine stimuli on striatal dopamine overflow in young versus aged F344 rats:  effects of stimulus concentration and order of administration.  Purdom MS, Stanford JA, Currier TD and Gerhardt GA.  Brain Res, 979:203-209, 2003.
  32. Decreased plasma membrane expression of striatal dopamine transporter in aging.  Salvatore MF, Apparsundaram S, and Gerhardt GA.  Neurobio Aging, 24:1147-1154, 2003.
  33. Chloral hydrate and ethanol, but not urethane, alter the clearance of exogenous dopamine recorded by chronoamperometry in striatum of freely-moving rats. Sabeti J, Gerhardt GA and Zahniser NR.  Neurosci Lett 343(1):9-12, 2003.
  34. Intraputamenal infusion of GDNF in aged rhesus monkeys:  distribution and dopaminergic effects. Yi A, Markesbery W, Zhang Z, Grondin E, Gerhardt GA, and Gash, DM.  J Comp Neurol 23;461(2):250-61, 2003.
  35. Individual differences in cocaine-induced locomotor sensitization in rats are associated with initial locomotor responsiveness to cocaine and differential inhibition of dopamine clearance in nucleus accumbens by cocaine. Sabeti J, Gerhardt GA and Zahniser NR. J Pharm Exp Ther. 305(1):180-90, 2003.
  36. The noradrenergic system of aged GDNF heterozygous mice.  Zaman V, Li Z, Middaugh L, Ramamoorth S, Rohrer B, Nelson ME, Tomac AC, Hoffer BJ, Gerhardt GA and Granholm A-Ch.  Cell Trans 12(3):291-303, 2003.
  37. Dopaminergic Modulation of the P50 Auditory Evoked Potential in a Computer Model of the CA3 Region of the Hippocampus:  Its Relationship to Sensory Gating in Schizophrenia. Moxon, K.A., Gerhardt GA, Adler, L.E.   Biol Cybern 88(4):265-75, 2003.
  38. Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys.  Grondin R, Cass WA, Zhang Z, Stanford JA, Gash DM and Gerhardt, GA.  J Neurosci 23(5):1974-1980, 2003.
  39. Differences in spontaneous motor activity and orolingual motor function between young vs. aged Fischer 344 rats: Relationships with nigrostriatal neurochemical measures.  Stanford JA, Vorontsova E, Surgener SP, Gerhardt GA, and Fowler SC.  Neurobio Aging, 24(2):259-66, 2003.
  40. Quantitative analysis of striatal clearance of exogenous dopamine, recorded by chronoamperometry in the freely-moving rat.Sabeti J, Adams CE, Gerhardt GA, and Zahniser, NR.    J Neurosci Meth 121(1):41-52, 2002.
  41. Acute cocaine differentially alters accumbens and striatal dopamine clearance in low and high cocaine locomotor responders: behavioral and electrochemical recordings in freely-moving rats.Sabeti J, Gerhardt GA, and Zahniser, NR.   JPET 302(3):1201-11, 2002..
  42. Chronic, controlled striatal delivery of GDNF promotes nigrostriatal dopaminergic regeneration and behavioral recovery in parkinsonian monkeys. Grondin, R., Zhang, Z., Yi, A., Maswood, N., Cass, W.A., Andersen, A.H., Elsberry, D.D., Klein, M.C., Gerhardt GA, and Gash, D.M.  Brain 125(10):2191-2201, 2002.
  43. Effects of chronic intraputamenal infusion of Glial cell line-derived neurotrophic factor (GDNF) in aged rhesus monkeys.  Maswood N, Grondin R, Zhang Z, Stanford JA, Surgener SP, Gash DM, and Gerhardt GA.  Neurobio Aging 23(5):881, 2002.
  44. Adeno associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion.  McGrath J, Lintz E., Hoffer BJ, Gerhardt GA, Quintero EM, and Granholm A-C.  Cell Trans, 11(3):215-27, 2002.
  45. Nicotinic acetylcholine receptors interact with dopamine in induction of striatal long-term depression.  Partridge JG, Apparsundaram, S, Gerhardt GA, Ronesi J and Lovinger DM.  J Neurosci 22(7):2542-2549, 2002.
  46. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys.Gerhardt GA, Cass WA, Yi A, Zhang, Z and Gash, DM.    J Neurochem 80:168-177, 2002.
  47. Aged F344 Rats Exhibit an Increased Proportion of Dopamine Agonist-Excited Striatal Neurons.Stanford, J.A., Gash, C.R., and Gerhardt GA.    Neurobiology of Aging 23(2):263-270, 2002.
  48.  Neuroprotection of grafted neurons with a GDNF/caspase inhibitor cocktail.Helt, C.E., Hoernig, G.R., Albeck, D.S., Gerhardt GA, Ickes, B., Reyland, M.E., Quissell, D.O., Stromberg, I., Granholm, A.-C.  Exp Neurol 170(2):258-69, 2001.
  49. Effects of age and GDNF on noradrenergic innervation of the hippocampal: Studies from intraocular grafts. Granholm, A-Ch, Helt, C., Srivastava, N., Backman, C., and Gerhardt GA.   Microsc Res Tech 54(5):298-308, 2001.
  50. Age-related changes in striatal function of freely moving F344 rats. Stanford, JA and Gerhardt GA.  Neurobiol Aging 22(4):659-69, 2001.
  51. Nomifensine reveals age-related changes in K+-evoked striatal DA overflow in F344 rats. Stanford, J.A., Currier, T.D., Purdom, M.S., and Gerhardt GA.  Neurobiol Aging, 22(3):495-502, 2001.
  52.  Intranigral Transplantation of Solid Tissue Ventral Mesencephalon or Striatal Grafts Induces Behavioral Recovery in 6-OHDA-Lesioned Rats.  Palmer, M.R., Granholm, A.-C., van Horne, C.G., Giardina, K.E., Fruend, R.K., Moorhead, J.W., and Gerhardt GA. Brain Res 890(1):86-99, 2001.
  53. Motor slowing and Parkinsonian Signs in Aging Rhesus Monkeys Mirror Human Aging. Zhang, Z., Andersen, A., Smith, C., Grondin, R., Gerhardt GA, and Gash, D.  J Gerontology: Biological Sciences 55A(10): B473-B480, 2000.
  54. Dopaminergic therapy improves upper limb motor performance in aged rhesus monkeys. Grondin, R., Zhang, Z, Gerhardt GA and Gash D.M.   Ann of Neurol 48(2): 250-253, 2000.
  55. Glial Cell Line-Derived Neurotrophic Factor is Essential for Postnatal Survival of Midbrain Dopamine Neurons.  Granholm, A-C, Reyland, M., Albeck, D., Sanders, L., Gerhardt GA, Hoernig, G., Shen, L., Westphal, H., and Hoffer, B.  J. Neurosci. 20(9):3182-3190, 2000.
  56. In vivo microdialysis studies of age-related alterations in potassium-evoked overflow of dopamine in the dorsal striatum of Fischer 344 rats.  Stanford, J.A., Giardina, K., and Gerhardt GA. Int. J. Develop. Neurosci. (18)4-5:411-416, 2000.
  57. Multiple single-unit recordings in the striatum of freely moving animals: Effects of apomorphine and d-amphetamine in normal and unilateral 6-hydroxydopamine-lesioned rats.  Kish, L.J., Palmer, M.R. and Gerhardt GA.  Brain Res. 833:58-70, 1999.
  58. Differences in the pharmacological properties of dopamine release between the substantia nigra and striatum: an in vivo electrochemical study.  Hoffman, A.F. and Gerhardt GA.  JPET, 289:455-463, 1999.
  59. Age-related reductions in [3H] 35,428 binding to the dopamine transporter in nigrostriatal and mesolimbic brain regions of the Fischer 344 rat.  Hebert, M.A., Larson, G.A., Zahniser, N.R., and Gerhardt GA.  JPET, 288:1334-1339, 1999.
  60. Voltage-dependency of the dopamine transporter in the rat substantia nigra.  Hoffman, A.F., Zahniser, N.R., Lupica, C.R., and Gerhardt GA.  Neurosci. Lett., 260:105-108, 1999.
  61.  In vivo dopamine clearance rate in rat striatum: regulation by extracellular dopamine concentration and dopamine transporter inhibitors.  Zahniser, N.R., Larson, G.A., and Gerhardt GA.JPET, 289:266-277, 1999.
  62. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned Rhesus monkeys. Gerhardt GA, Cass, W.A., Huettl, P., Brock, S., Zhang, Z., and Gash, D.M.   Brain Res., 817:163-171, 1999.
  63. Methodology for coupling local application of dopamine and other chemicals with rapid in vivo electrochemical recordings in freely moving rats.  Gerhardt GA, Ksir, C., Pivik, C., Dickinson, S.D., Sabeti, J., and Zahniser, N.R.  J. Neurosci. Meth., 87:67-76, 1999.
  64. Microdialysis studies of basal levels and stimulus-evoked overflow of dopamine and metabolites in the striatum of young and aged Fischer 344 rats.  Gerhardt GA and Maloney, R.E.  Brain Res., 816:68-77, 1999.
  65. Age-related changes in the capacity, rate and modulation of dopamine uptake within the striatum and nucleus accumbens of Fischer 344 rats:  An in vivo electrochemical study.  Hebert, M.A. and Gerhardt GA.  JPET, 288:879-887, 1999.
  66. Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum.  Dickinson, S.D., Sabeti, J., Larson, G.A., Giardina, K., Rubinstein, M., Kelly, M.A., Grandy, D.K., Low, M.J., Gerhardt GA, and Zahniser, N.R.  J. Neurochem., 72:148-156, 1998.
  67. Dopamine transporter activity in the substantia nigra and striatum assessed by high-speed chronoamperometric recordings in brain slices.  Hoffman, A.F., Lupica, C.R., and Gerhardt GA. J. Pharmacol. Exp. Therapeut., 287:487-496, 1998.
  68. In vivo electrochemical studies of dopamine clearance in subregions of rat nucleus accumbens:  differential properties of the core and shell. David, D., Zahniser, N.R., Hoffer, B.J., and Gerhardt GA.  Exp. Neurol., 153:277-286, 1998.
  69. Age-related decline in striatal dopamine release and motoric function in brown Norway/Fischer 344 hybrid rats. Yurek, D.M., Hipkens, S.B., Gash, D.M., and Gerhardt GA.   Brain Res., 791:246-256, 1998.
  70. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background and developmental adaptations.  Kelly, M.A., Rubinstein, M., Lessov, C.N., Burkhart-Kasch, S., Zhang, G., Saez, C., Bunzow, J.R., Fang, Y., Gerhardt GA, Phillips, T.J., Grandy, D.K., and Low, M.J.  J. Neurosci., 18:3470-3479, 1998.
  71. Kidney cografts enhance fiber outgrowth from ventral mesencephalic grafts to the 6-OHDA-lesioned striatum and improve behavioral recoveryGranholm, A.-Ch., Henry, S., Hebert, M., Eken, S., Gerhardt G, and van Horne, C.  .  Cell Transplant., 7:197-212,  1998.
  72. In vivo electrochemical studies of dopamine clearance in the rat substantia nigra:  effects of locally applied uptake inhibitors and unilateral 6-OHDA lesions.  Hoffman, A.F. and Gerhardt GA.  J. Neurochem., 70:179-189, 1998.
  73.  In vivo electrochemical measurements of serotonin clearance in rat striatum:  effects of neonatal 6-hydroxydopamine-induced serotonin hyperinnervation and serotonin uptake inhibitors. Luthman, J., Friedemann, M.N., Hoffer, B.J., and Gerhardt GA.  J. Neural Tran., 104:379-397, 1997.
  74. Effects of ethanol on striatal dopamine overflow and clearance:  An in vivo electrochemical study.  Wang, Y., Palmer, M.R., Cline, E.J., and Gerhardt GA.  Alcohol, 14:593-601, 1997.
  75. Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-OHDA lesioned striatum. Granholm, A.-Ch., Mott, J.L., Eken, S., van Horne, C., Bowenkamp, K., Hoffer, B., Henry, S., and Gerhardt GA..   Exp. Brain Res., 116:29-38, 1997.
  76. Behavioral and neurochemical effects of intranigral GDNF administration on aged Fischer 344 rats. Hebert, M.A. and Gerhardt GA.  J. Pharmacol. Exp. Therapeut., 282:760-768, 1997.
  77. Caloric restriction enhances evoked DA overflow in striatum and nucleus accumbens of aged Fischer 344 rats.  Diao, L.H., Bickford, P.C., Stevens, J.O., Cline, E.J., and Gerhardt GA.  Brain Res., 763:276-280, 1997.
  78. The effects of local application of ethanol in the n. accumbens on dopamine overflow and clearance.  Samson, H.H., Hodge, C.W., Erickson, H.L., Niehus, J.S., Gerhardt GA, Kalivas, P.W., and Floyd, E.A.  Alcohol, 14:485-492, 1997.
  79. In vivo microdialysis studies of somatodendritic dopamine release in the rat substantia nigra:  effects of unilateral 6-OHDA lesions and GDNF.  Hoffman, A.F., van Horne, C.G., Eken, S., Hoffer, B.J. and Gerhardt G.  Exp. Neurology, 147:130-141, 1997.
  80. Functional effects of GDNF in normal rat striatum:  Presynaptic studies using in vivo electrochemistry and microdialysis. Hebert, M.A., van Horne, C.G., Hoffer, B.J., and Gerhardt GA.   J. Pharmacol. Exp. Therapeut., 279:1181-1190, 1996.
  81. Functional recovery in parkinsonian monkeys treated with GDNF. Gash, D.M., Zhiming, Z., Ovadia, A., Cass, W., Yi, A., Simmerman, L., Russell, D., Lapchak, P., Collins, F., Hoffer, B.J., and Gerhardt GA..   Nature, 380:252-255, 1996.
  82. In vivo electrochemical studies of the dynamic effects of locally applied excitatory amino acids in the striatum of the anesthetized rat. Friedemann, M.N. and Gerhardt GA..   Exp. Neurol., 138:53-63, 1996.
  83. In vivo electrochemical studies of dopamine overflow and clearance in the striatum of normal and MPTP-treated rhesus monkeys. Gerhardt GA, Cass, W.A., Hudson, J., Henson, M., Zhang, Z., Ovadia, A., Ketonen, E., Hoffer, B.J., and Gash, D.M. J. Neurochem., 66:579-588, 1996.
  84. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys.Gash, D.M., Zhang, Z., Cass, W.A., Ovadia, A., Martin, D., Russell, D., Collins, F., Hoffer, B.J., and Gerhardt G.     J. Comp. Neurol., 363:345-358, 1995.
  85. Age-related changes in potassium-evoked overflow of dopamine in the striatum of the rhesus monkey.  Gerhardt GA, Cass, W.A., Henson, M., Zhang, Z., Ovadia, A., Hoffer, B.J., and Gash, D.M.  Neurobiology of Aging, 16(6):939-946, 1995.
  86. Medial dorsal striatum is more sensitive than lateral dorsal striatum to cocaine inhibition of exogenous dopamine clearance: Relation to striosome/matrix and [3H] mazindol binding.Cline, E.J., Adams, C.E., Larson, G.A., Gerhardt GA, and Zahniser, N.R.  Exp. Neurology, 134:135-149, 1995.
  87. In vivo assessment of dopamine uptake in rat medial prefrontal cortex:  Comparison with dorsal striatum and nucleus accumbens.  Cass, W.A. and Gerhardt GA..  J. Neurochem., 65:201-207, 1995.
  88. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. Bowenkamp, K.E., Hoffman, A.F., Gerhardt GA, Henry, M.A., Biddle, P.T., Hoffer, B.J., and Granholm, A-C.E.   J. Comparative Neurology, 355:479-489, 1995.
  89. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivoHudson, J., Granholm, A-C., Gerhardt GA, Henry, M.A.,  Hoffman, A., Biddle, P., Leela, N.S., Mackerlova, L., Lile, J.D., Collins, F., and Hoffer, B.J.  .  Brain Res. Bull., 36:425-432, 1995.
  90. Increased dopamine clearance in the non-lesioned striatum of Rhesus monkeys with unilateral MPTP striatal lesionsCass, W.A., Gerhardt GA, Zhang, Z., Ovadia, A. and Gash, D.M.  .  Neurosci. Letters 185:52-55, 1995.
  91. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Hoffer, B.J., Hoffman, A., Bowenkamp, K., Huettl, P., Hudson, J., Martin, D., Line, L-F. and Gerhardt GA..   Neurosci. Lett. 182:107-111, 1994.
  92. Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake.  Cass, W.A. and Gerhardt GA.. Neurosci. Lett., 176:259-263, 1994.
  93. Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: Role of metabolism and effects of locally applied uptake inhibitors.  Cass, W.A., Zahniser, N.R., Flach, K.A. and Gerhardt GA..  J. Neurochem., 61:2269-2278, 1993.
  94. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Hudson, J.L., van Horne, C.G., Strömberg, I., Brock, S., Clayton, J., Masserano, J., Hoffer, B.J. and Gerhardt GA..   Brain Res. 626:167-174, 1993.
  95.  In vivo electrochemical measurements of exogenous dopamine clearance in normal and neonatal 6-hydroxydopamine-treated rat striatum.  Luthman, J., Friedemann, M.N., Hoffer, B.J. and Gerhardt GA.. Exp. Neurol., 122:273-282, 1993.
  96. Reduced clearance of exogenous dopamine in rat nucleus accumbens, but not in dorsal striatum, following cocaine challenge in rats withdrawn from repeated cocaine administration.Cass, W.A., Gerhardt GA, Gillespie, K., Curella, P., Mayfield, R.D. and Zahniser, N.R.   J. Neurochem., 61:273-283, 1993.
  97. In vivo electrochemical measurements and electrophysiological studies of rat striatum following neonatal 6-hydroxydopamine treatment.  Luthman, J., Friedemann, M., Bickford, P., Olson, L., Hoffer, B.J. and Gerhardt GA..  Neuroscience 52:677-687, 1993.
  98. Clearance and diffusion of locally applied dopamine in normal and 6-hydroxydopamine-lesioned rat striatum.  J. Pharmacol.van Horne, C., Hoffer, B.J., Strömberg, I. and Gerhardt GA.   Exp. Ther. 263:1285-1292, 1992.
  99.  Eighteen-month course of two patients with grafts of fetal dopamine neurons for severe Parkinson's disease. Hoffer, B.J., Leenders, K.L., Young, D., Gerhardt G, Zerbe, G.O., Bygdeman, M., Seiger, Å., Olson, L., Strömberg, I. and Freedman, R. Exp. Neurol., 118:243-252, 1992.
  100. Direct in vitro electrochemical measurement of dopamine overflow in intermediate pituitary: characterization and pharmacology. Williams, P.J., Dunwiddie, T.V. and Gerhardt GA..J. Pharm. Exp. Ther. 261:403-411, 1992.
  101. Differences in dopamine clearance and diffusion in rat striatum and nucleus accumbens following systemic cocaine administration. Cass, W.A., Gerhardt GA, Mayfield, R.D., Curella, P. and Zahniser, N.R. J. Neurochem. 59:259-266, 1992.
  102. Regional effects of aging on dopaminergic function in the Fischer 344 rat. Friedemann, M.N. and Gerhardt GA.. Neurobiology of Aging 13:325-332, 1992.
  103. Effects of dopamine receptor agonists and antagonists on catecholamine release in bovine chromaffin cells.Huettl, P., Gerhardt GA, Browning, M.D. and Masserano, J.M.  J. Pharmacol. Exp. Ther. 257(2): 567-574, 1991.
  104. Dopamine D2 receptor agonists inhibit the calcium-evoked release of endogenous dopamine from striatal synaptosomes.Masserano, J.M., Bowyer, J.F. and Gerhardt GA..  Annals of the New York Academy of Sciences, 604:629-631, 1990. 
  105. The effects of cholecystokinin (CCK-8) on dopamine containing nerve terminals in the caudate nucleus and nucleus accumbens of the anesthetized rat: An in vivo ‑electrochemical study. Gerhardt GA, Friedemann, M., Brodie, M.S., Vickroy, T.W., Gratton, A.P., Hoffer, B.J. and Rose, G.M. Brain Res., 499: 157-163, 1989.
  106. In vivo electrochemical studies of the effects of N-methyl-D-aspartate (NMDA) on dopamine nerve terminals in the neostriatum of the anesthetized rat.Friedemann, M. and Gerhardt GA..   Proc. West Pharmacol. Soc. 32: 143-147, 1989.
  107.  Human fetal mesencephalic tissue grafted to dopamine-denervated striatum of athymic rats: Light- and electron-microscopical histochemistry and in vivo chronoamperometric studies. Strömberg, I., Almqvist, P., Bygdeman, M., Finger, T., Gerhardt G, Granholm, A.-Ch., Mahalik, T., Seiger, A., Hoffer, B. and Olson, L. J. Neurosci., 9: 614-624, 1989.
  108. Outflow and overflow of picogram levels of endogenous dopamine and DOPAC from rat striatal slices: Improved methodology for studies of stimulus-evoked release and metabolism. Gerhardt GA, Dwoskin, L.P. and Zahniser, N.R.  J. Neurosci. Meth., 26: 217-227, 1989.
  109.  Effects of electrical stimulation of brain reward sites on release of dopamine in rat: An in vivo electrochemical study. Gratton, A., Hoffer, B.J. and Gerhardt GA.Brain Res. Bull., 21: 319-324, 1988.
  110.  Potentiation of morphine-elicited circling by dopaminergic uptake blockade. Gratton, A., Hoffer, B.J., Gerhardt GA and Wise, R.A.Pharmacol. Biochem. Behav., 30: 1077-1079, 1988. 
  111. In vivo electrochemical studies of the effects of cocaine on dopamine nerve terminals in the rat neostriatum. Gerhardt GA, Gratton, A. and Rose, G.M.  Physiologia Bohemoslovaca, 37: 249-257, 1988.
  112. The effects of delta-9-tetrahydrocannabinol on potassium-evoked release of dopamine in rat caudate nucleus: An in vivo electrochemical and in vivo microdialysis study. Ng Cheong Ton, J.M., Gerhardt GA, Friedemann, M., Etgen, A.M., Rose, G.M., Sharpless, N.S. and Gardner, E.L. Brain Res., 451: 59-68, 1988. 
  113. Modulation of the gating of auditory evoked potentials by norepinephrine and dopamine: Pharmacological evidence obtained using a selective neurotoxin. Adler, L.E., Pang, K., Gerhardt G and Rose, G. Biological Psychiatry, 24: 179-190, 1988.
  114. Reproducibility of the measurement of plasma noradrenergic and dopaminergic metabolites in normal subjects. Baker, N.J., Adler, L.E., Waldo, M., Gerhardt G, Drebing, C., Cox, B., Berry, S., Macdonald, M., Phillips, W. and Freedman, R. Psychiatry Res. 23:119-130, 1988.
  115.  Release of monoamines from striatum of rat and mouse evoked by local application of potassium: Evaluation of a new in vivo electrochemical technique.  Gerhardt GA, Rose, G.M. and Hoffer, B.J. J. Neurochem., 46: 842-850, 1986.
  116. Age-related alterations in monoamine release from rat striatum: An in vivo electrochemical study.  Rose, G.M., Gerhardt GA, Conboy, G.L. and Hoffer, B.J. Neurobiol. of Aging, 7: 77-82, 1986.
  117.  Dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse:  An in vivo electrochemical study.  Gerhardt G, Rose, G., Strömberg, I., Conboy, G., Olson, L., Jonsson, G. and Hoffer, B. J. Pharmacol. Exp. Ther., 235: 259-265, 1985.
  118. Monoamine release from dopamine-depleted rat caudate nucleus reinnervated by substantia nigra transplants:  An in vivo electrochemical study. Rose, G., Gerhardt G, Strömberg, I., Olson, L. and Hoffer, B.   Brain Res., 341: 92-100, 1985.
Partners in Advancing Parkinson's Disease Research and Treatment
Morris K. Udall Centers of Excellence for Parkinson's Disease Research
Comments to Francois Pomerleau, Last Modified: October 14, 2010
Copyright © 2010, University of Kentucky Chandler Medical Center
Terms, Conditions & Privacy Statement